Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30119% above fair value
$43.65+0.41 (+0.95%)
Close on Nov 12, 2026Market cap $50.87BP/E 72.8Yield –
Teva Pharmaceutical Industries cash
Cash and short-term investments held at the end of each period.
Teva Pharmaceutical Industries's cash was $3.66B at Jun 30, 2026. For fiscal 2025 it was $3.56B, up 7.8% from the year before. Over ten years it grew -6.5% a year on average. The highest annual figure on record is $6.95B in fiscal 2015.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.56B | +7.8% |
| FY2024 | Dec 31, 2024 | $3.30B | +2.3% |
| FY2023 | Dec 31, 2023 | $3.23B | +13.8% |
| FY2022 | Dec 31, 2022 | $2.83B | +28.9% |
| FY2021 | Dec 31, 2021 | $2.20B | +1.0% |
| FY2020 | Dec 31, 2020 | $2.18B | +10.2% |
| FY2019 | Dec 31, 2019 | $1.98B | +10.8% |
| FY2018 | Dec 31, 2018 | $1.78B | +85.0% |
| FY2017 | Dec 31, 2017 | $963.00M | -2.5% |
| FY2016 | Dec 31, 2016 | $988.00M | -85.8% |
| FY2015 | Dec 31, 2015 | $6.95B | +212.0% |
| FY2014 | Dec 31, 2014 | $2.23B | +114.5% |
| FY2013 | Dec 31, 2013 | $1.04B | -63.9% |
| FY2012 | Dec 31, 2012 | $2.88B | +162.7% |
| FY2011 | Dec 31, 2011 | $1.10B | -14.6% |
| FY2010 | Dec 31, 2010 | $1.28B | -42.9% |
| FY2009 | Dec 31, 2009 | $2.25B | +17.9% |
| FY2008 | Dec 31, 2008 | $1.91B | +28.2% |
| FY2007 | Dec 31, 2007 | $1.49B | +11.7% |
| FY2006 | Dec 31, 2006 | $1.33B | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.66B | +69.1% |
| Q1 FY2026 | Mar 31, 2026 | $3.74B | +120.4% |
| Q4 FY2025 | Dec 31, 2025 | $3.56B | +7.8% |
| Q3 FY2025 | Sep 30, 2025 | $2.20B | -33.6% |
| Q2 FY2025 | Jun 30, 2025 | $2.16B | -4.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.70B | -43.3% |
| Q4 FY2024 | Dec 31, 2024 | $3.30B | +2.3% |
| Q3 FY2024 | Sep 30, 2024 | $3.32B | +47.6% |
| Q2 FY2024 | Jun 30, 2024 | $2.26B | -15.4% |
| Q1 FY2024 | Mar 31, 2024 | $2.99B | +37.5% |
| Q4 FY2023 | Dec 31, 2023 | $3.23B | +13.8% |
| Q3 FY2023 | Sep 30, 2023 | $2.25B | +1.1% |
| Q2 FY2023 | Jun 30, 2023 | $2.67B | +27.7% |
| Q1 FY2023 | Mar 31, 2023 | $2.18B | -3.3% |
| Q4 FY2022 | Dec 31, 2022 | $2.83B | +28.9% |
| Q3 FY2022 | Sep 30, 2022 | $2.23B | +8.8% |
| Q2 FY2022 | Jun 30, 2022 | $2.09B | -14.2% |
| Q1 FY2022 | Mar 31, 2022 | $2.25B | +29.1% |
| Q4 FY2021 | Dec 31, 2021 | $2.20B | +1.0% |
| Q3 FY2021 | Sep 30, 2021 | $2.05B | +11.9% |
| Q2 FY2021 | Jun 30, 2021 | $2.44B | +1.4% |
| Q1 FY2021 | Mar 31, 2021 | $1.74B | -3.4% |
| Q4 FY2020 | Dec 31, 2020 | $2.18B | +10.2% |
| Q3 FY2020 | Sep 30, 2020 | $1.83B | +47.2% |
| Q2 FY2020 | Jun 30, 2020 | $2.40B | +10.9% |
| Q1 FY2020 | Mar 31, 2020 | $1.80B | -8.6% |
| Q4 FY2019 | Dec 31, 2019 | $1.98B | +10.8% |
| Q3 FY2019 | Sep 30, 2019 | $1.24B | -33.8% |
| Q2 FY2019 | Jun 30, 2019 | $2.17B | +16.3% |
| Q1 FY2019 | Mar 31, 2019 | $1.97B | +39.1% |
| Q4 FY2018 | Dec 31, 2018 | $1.78B | +85.0% |
| Q3 FY2018 | Sep 30, 2018 | $1.88B | +175.7% |
| Q2 FY2018 | Jun 30, 2018 | $1.86B | +210.7% |
| Q1 FY2018 | Mar 31, 2018 | $1.42B | +57.6% |
| Q4 FY2017 | Dec 31, 2017 | $963.00M | -2.5% |
| Q3 FY2017 | Sep 30, 2017 | $680.00M | -56.3% |
| Q2 FY2017 | Jun 30, 2017 | $599.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $900.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $988.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.56B | – |
See a number that looks wrong?